Flavoxate

CHEMBL1493 Phase 4 Aprovado Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
391.5 g/mol
LogP
4.3
Phase
4

This medication relaxes the smooth muscle of the bladder to relieve urinary urgency, frequency, and pain associated with various urinary tract conditions. It works by blocking calcium channels and has mild anticholinergic and analgesic properties.

Peso Molecular

391,5000 g/mol

LogP

4,30

TPSA

55,80 Ų

Regra dos 5 de Lipinski

Aprovado

Áreas Terapêuticas

Mecanismo de Ação

Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mecanismo

Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.

Estrutura 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

Cc1c(-c2ccccc2)oc2c(C(=O)OCCN3CCCCC3)cccc2c1=O

InChI

InChI=1S/C24H25NO4/c1-17-21(26)19-11-8-12-20(23(19)29-22(17)18-9-4-2-5-10-18)24(27)28-16-15-25-13-6-3-7-14-25/h2,4-5,8-12H,3,6-7,13-16H2,1H3

Molecular Formula

C24H25NO4

HBD / HBA

- / 5

Ligações Rotacionáveis

6

Átomos Pesados

29

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Perguntas frequentes

This medication relaxes the smooth muscle of the bladder to relieve urinary urgency, frequency, and pain associated with various urinary tract conditions. It works by blocking calcium channels and has mild anticholinergic and analgesic properties.

Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.

Yes, Flavoxate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1493. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 3354. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Aviso Médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.